RE:Cxr selloffThe only shorts I see here are maybe the retail. I rather be outnumbered than outsmarted. Show me the latest short interest report that supports their presence. The last time I saw something like this was when Chelsea Therapeutics new drug, Northera, just received FDA approval for orthostatic hypotension back in 2014. They were bought out within about 2 weeks I believe. What a roller coaster, lots of bear raids, buzz bombing for stop limits, etc. Anyway, that's besides the point. CXR has potential to generate some serious revenue even without the opportunity that Canada is moving towards a National Formulary very soon. Ranks as strong buy by me add I am in my 3rd decade with pharma. GLTA